Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Tempest Therapeutics stock
Learn how to easily invest in Tempest Therapeutics stock.
Tempest Therapeutics is a biotechnology business based in the US. Tempest Therapeutics shares (TPST) are listed on the NASDAQ and all prices are listed in US Dollars. Tempest Therapeutics employs 17 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Tempest Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – TPST. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Tempest Therapeutics stock price (NASDAQ: TPST)Use our graph to track the performance of TPST stocks over time.
Tempest Therapeutics shares at a glance
|Latest market close||$2.04|
|52-week range||$1.06 - $4.55|
|50-day moving average||$1.57|
|200-day moving average||$2.19|
|Wall St. target price||$17.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$8.63|
Buy Tempest Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Tempest Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Tempest Therapeutics price performance over time
|1 week (2023-01-23)||2.00%|
|1 month (2022-12-30)||77.39%|
|3 months (2022-10-28)||4.62%|
|6 months (2022-07-29)||0.49%|
|1 year (2022-01-28)||-44.86%|
|2 years (2021-01-29)||3.55%|
|3 years (2020-01-30)||8.46|
|5 years (2018-01-30)||87.16%|
Is Tempest Therapeutics stock undervalued or overvalued?
Valuing Tempest Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tempest Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tempest Therapeutics's P/E ratio
Tempest Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Tempest Therapeutics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Tempest Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-29.87%|
|Return on equity TTM||-97.81%|
|Market capitalisation||$21.5 million|
TTM: trailing 12 months
Tempest Therapeutics share dividends
We're not expecting Tempest Therapeutics to pay a dividend over the next 12 months.
Have Tempest Therapeutics's shares ever split?
Tempest Therapeutics's shares were split on a 1:15 basis on 27 June 2021. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tempest Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Tempest Therapeutics shares which in turn could have impacted Tempest Therapeutics's share price.
Tempest Therapeutics overview
Tempest Therapeutics Inc. , a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Frequently asked questionsWhat percentage of Tempest Therapeutics is owned by insiders or institutions?
Currently 3.248% of Tempest Therapeutics shares are held by insiders and 71.251% by institutions. How many people work for Tempest Therapeutics?
Latest data suggests 17 work at Tempest Therapeutics. When does the fiscal year end for Tempest Therapeutics?
Tempest Therapeutics's fiscal year ends in December. Where is Tempest Therapeutics based?
Tempest Therapeutics's address is: 7000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Tempest Therapeutics's ISIN number?
Tempest Therapeutics's international securities identification number is: US87978U1088
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert